Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix 3-Month Depot in Prostate Cancer
NCT00116753Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jan 2005
- Primary completion
- Nov 2006
- Modality
- Peptides, Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of degarelix in prostate cancer (PCa) (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Number of Participants With Testosterone Level <=0.5 ng/mL From Day 28 Until the End of the Study. Started Jan 2005; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00116753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116753.